TapImmune President and CEO, Peter Hoang, will be presenting at the 29th Annual Piper Jaffray Healthcare Conference.
Chairman and Strategic Advisor Glynn Wilson, Ph.D., and Senior Director of Molecular Biology & Virology Robert Florkiewicz, Ph.D., will give an oral presentation titled, “Increasing the potency of DNA-based immunotherapies using PolyStart™ peptide expression system,” at the World Vaccine & Immunotherapy Congress West Coast, held Thursday, November 30 – December 1, 2017, at the Loews Coronado Bay Resort in San Diego, CA.
US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to treat triple-negative breast cancer (TNBC).
Please join us for TapImmune’s third quarter 2017 corporate and clinical update today, Novmber 15th at 4:30pm ET.
TapImmune has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer.
Triple-negative breast cancer is a difficult-to-treat condition, but one where patients may stand to benefit significantly from immunotherapies that are effective at continually fighting off disease progression long after initial cancer therapy. As a multi-peptide therapeutic vaccine, TPIV200 is designed to do just that.
Please join us for our third quarterly call update of 2017 on November 15, 2017 at 4:30pm.